These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 8296903)
1. Effects on behavior of modulation of gonadal function in men with gonadotropin-releasing hormone antagonists. Loosen PT; Purdon SE; Pavlou SN Am J Psychiatry; 1994 Feb; 151(2):271-3. PubMed ID: 8296903 [TBL] [Abstract][Full Text] [Related]
2. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate. Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948 [TBL] [Abstract][Full Text] [Related]
3. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido. Pavlou SN; Brewer K; Farley MG; Lindner J; Bastias MC; Rogers BJ; Swift LL; Rivier JE; Vale WW; Conn PM J Clin Endocrinol Metab; 1991 Dec; 73(6):1360-9. PubMed ID: 1955518 [TBL] [Abstract][Full Text] [Related]
4. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. Bagatell CJ; Matsumoto AM; Christensen RB; Rivier JE; Bremner WJ J Clin Endocrinol Metab; 1993 Aug; 77(2):427-32. PubMed ID: 8345047 [TBL] [Abstract][Full Text] [Related]
5. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. Swerdloff RS; Bagatell CJ; Wang C; Anawalt BD; Berman N; Steiner B; Bremner WJ J Clin Endocrinol Metab; 1998 Oct; 83(10):3527-33. PubMed ID: 9768659 [TBL] [Abstract][Full Text] [Related]
6. A comparison of the suppressive effects of testosterone and a potent new gonadotropin-releasing hormone antagonist on gonadotropin and inhibin levels in normal men. Bagatell CJ; McLachlan RI; de Kretser DM; Burger HG; Vale WW; Rivier JE; Bremner WJ J Clin Endocrinol Metab; 1989 Jul; 69(1):43-8. PubMed ID: 2499592 [TBL] [Abstract][Full Text] [Related]
7. Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men. Pavlou SN; Wakefield G; Schlechter NL; Lindner J; Souza KH; Kamilaris TC; Konidaris S; Rivier JE; Vale WW; Toglia M J Clin Endocrinol Metab; 1989 Feb; 68(2):446-54. PubMed ID: 2537334 [TBL] [Abstract][Full Text] [Related]
8. Suppression of pituitary-gonadal function by a potent new luteinizing hormone-releasing hormone antagonist in normal men. Pavlou SN; Wakefield GB; Island DP; Hoffman PG; LePage ME; Chan RL; Nerenberg CA; Kovacs WJ J Clin Endocrinol Metab; 1987 May; 64(5):931-6. PubMed ID: 3104388 [TBL] [Abstract][Full Text] [Related]
9. Single subcutaneous doses of a luteinizing hormone-releasing hormone antagonist suppress serum gonadotropin and testosterone levels in normal men. Pavlou SN; Debold CR; Island DP; Wakefield G; Rivier J; Vale W; Rabin D J Clin Endocrinol Metab; 1986 Aug; 63(2):303-8. PubMed ID: 3088019 [TBL] [Abstract][Full Text] [Related]
10. Comparative effects of two different delivery systems on gonadotropin-releasing hormone (GnRH) antagonist-induced suppression of gonadotropins and testosterone in man. Salameh W; Bhasin S; Steiner BS; McAdams LA; Peterson M; Rivier JE; Vale WW; Swerdloff RS J Androl; 1994; 15(1):22-8. PubMed ID: 8188535 [TBL] [Abstract][Full Text] [Related]
11. Persistence of concordant luteinizing hormone (LH), testosterone, and alpha-subunit pulses after LH-releasing hormone antagonist administration in normal men. Pavlou SN; Veldhuis JD; Lindner J; Souza KH; Urban RJ; Rivier JE; Vale WW; Stallard DJ J Clin Endocrinol Metab; 1990 May; 70(5):1472-8. PubMed ID: 2110578 [TBL] [Abstract][Full Text] [Related]
12. Effects of endogenous testosterone and estradiol on sexual behavior in normal young men. Bagatell CJ; Heiman JR; Rivier JE; Bremner WJ J Clin Endocrinol Metab; 1994 Mar; 78(3):711-6. PubMed ID: 8126146 [TBL] [Abstract][Full Text] [Related]
13. High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteinizing hormone, follicle-stimulating hormone, and testosterone in normal men. Behre HM; Kliesch S; PĆ¼hse G; Reissmann T; Nieschlag E J Clin Endocrinol Metab; 1997 May; 82(5):1403-8. PubMed ID: 9141524 [TBL] [Abstract][Full Text] [Related]
14. Gonadotropin gene expression and secretion in gonadotropin-releasing hormone antagonist-treated male rats: effect of sex steroid replacement. Perheentupa A; Huhtaniemi I Endocrinology; 1990 Jun; 126(6):3204-9. PubMed ID: 1693570 [TBL] [Abstract][Full Text] [Related]
15. Gonadotropins and testosterone escape from suppression during prolonged luteinizing hormone-releasing hormone antagonist administration in normal men. Pavlou SN; Interlandi JW; Wakefield G; Island DP; Rivier J; Vale W; Kovacs WJ J Clin Endocrinol Metab; 1987 May; 64(5):1070-4. PubMed ID: 3104387 [TBL] [Abstract][Full Text] [Related]
16. Intermittent long-term administration of a potent gonadotropin-releasing hormone agonist in normal men. Doelle G; Linde R; Alexander N; Kirchner F; Vale W; Rivier J; Rabin D Int J Fertil; 1982; 27(4):234-7. PubMed ID: 6131043 [TBL] [Abstract][Full Text] [Related]
17. Concordant suppression of serum immunoreactive luteinizing hormone (LH), follicle-stimulating hormone, alpha subunit, bioactive LH, and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (detirelix). Andreyko JL; Monroe SE; Marshall LA; Fluker MR; Nerenberg CA; Jaffe RB J Clin Endocrinol Metab; 1992 Feb; 74(2):399-405. PubMed ID: 1370507 [TBL] [Abstract][Full Text] [Related]
18. Suppression of plasma gonadotropins and testosterone in adult male monkeys (Macaca fascicularis) by a potent inhibitory analog of gonadotropin-releasing hormone. Adams LA; Bremner WJ; Nestor JJ; Vickery BH; Steiner RA J Clin Endocrinol Metab; 1986 Jan; 62(1):58-63. PubMed ID: 3079603 [TBL] [Abstract][Full Text] [Related]
19. Gonadotropin and steroid secretory patterns during chronic treatment with a luteinizing hormone-releasing hormone agonist analog in men. Evans RM; Doelle GC; Alexander AN; Uderman HD; Rabin D J Clin Endocrinol Metab; 1984 May; 58(5):862-7. PubMed ID: 6423661 [TBL] [Abstract][Full Text] [Related]
20. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men. Behre HM; Klein B; Steinmeyer E; McGregor GP; Voigt K; Nieschlag E J Clin Endocrinol Metab; 1992 Aug; 75(2):393-8. PubMed ID: 1639941 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]